The data that support the findings of this study are available from the
corresponding author upon reasonable request.
References
1. Hunger, S.P., et al., Improved survival for children and
adolescents with acute lymphoblastic leukemia between 1990 and 2005: a
report from the children’s oncology group. Journal of clinical oncology
: official journal of the American Society of Clinical Oncology, 2012.30 (14): p. 1663-1669.
2. Ranta, S., et al., Cerebral sinus venous thromboses in children
with acute lymphoblastic leukaemia - a multicentre study from the Nordic
Society of Paediatric Haematology and Oncology. 2015.
3. Silverman, L.B., et al., Improved outcome for children with
acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol
91-01. Blood, 2001. 97 (5): p. 1211-8.
4. Ghanem, K.M., et al., Cerebral sinus venous thrombosis during
childhood acute lymphoblastic leukemia therapy: Risk factors and
management. Pediatric Blood & Cancer, 2017. 64 (12): p.
e26694.
5. Pui, C.H., et al., Treating childhood acute lymphoblastic
leukemia without cranial irradiation. N Engl J Med, 2009.360 (26): p. 2730-41.
6. Muwakkit, S., et al., Implementation of an intensive
risk-stratified treatment protocol for children and adolescents with
acute lymphoblastic leukemia in Lebanon. American Journal of
Hematology, 2012. 87 (7): p. 678-683.
7. Caruso, V., et al., Thrombotic complications in childhood acute
lymphoblastic leukemia: a meta-analysis of 17 prospective studies
comprising 1752 pediatric patients. Blood, 2006. 108 (7): p.
2216-22.
8. Musgrave, K.M., et al., Cerebral sinovenous thrombosis in
children and young adults with acute lymphoblastic leukaemia - a cohort
study from the United Kingdom. Br J Haematol, 2017. 179 (4): p.
667-669.
9. Tamim, H., R.R. Finan, and W.Y. Almawi, Prevalence of two
thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden)
and prothrombin G20210A, among healthy Lebanese. Thromb Haemost, 2002.88 (4): p. 691-2.
10. Nowak-Göttl, U., et al., Thromboembolic events in children
with acute lymphoblastic leukemia (BFM protocols): prednisone versus
dexamethasone administration. Blood, 2003. 101 (7): p.
2529-2533.
11. Kujovich, J.L., Factor V Leiden thrombophilia. Genet Med,
2011. 13 (1): p. 1-16.
12. Nowak-Göttl, U., et al., Prospective Evaluation of the
Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying
the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further
Prothrombotic Risk Factors. Blood, 1999. 93 (5): p. 1595-1599.
13. Raffini, L. and C. Thornburg, Testing children for inherited
thrombophilia: more questions than answers. British Journal of
Haematology, 2009. 147 (3): p. 277-288.
14. Tozuka, M., et al., Characterization of hypertriglyceridemia
induced by L-asparaginase therapy for acute lymphoblastic leukemia and
malignant lymphoma. Ann Clin Lab Sci, 1997. 27 (5): p. 351-7.
15. Ridola, V., et al., Severe acute hypertriglyceridemia during
acute lymphoblastic leukemia induction successfully treated with
plasmapheresis. Pediatr Blood Cancer, 2008. 50 (2): p. 378-80.
16. Finch, E.R., et al., Asparaginase formulation impacts
hypertriglyceridemia during therapy for acute lymphoblastic leukemia.Pediatric Blood & Cancer, 2020. 67 (1): p. e28040.
17. Bendjelid, K., Body habitus should not considerably affect the
interpretation of hemodynamic measurements: huge news? Crit Care Med,
2006. 34 (4): p. 1289-90.
18. Blatt, J., et al., Toxicity following concurrent intrathecal
and moderate-dose intravenous methotrexate. Leukemia, 1993.7 (11): p. 1734-7.
19. Franchini, M. and M. Makris, Non-O blood group: an important
genetic risk factor for venous thromboembolism. Blood Transfus, 2013.11 (2): p. 164-5.